top of page

Reducing heart disease disparities: The Alirocumab case study

Cardiovascular disease (CVD) is a leading cause of mortality worldwide, affecting millions of people from diverse racial and ethnic backgrounds. However, recent research has shed light on significant disparities in CVD risk profiles among different populations. For instance, African-American/Black (AA/B) individuals have been found to face a higher risk of CVD-related deaths compared to their White (W) counterparts. At the same time, some Hispanic/Latino (H/L) populations exhibit a higher prevalence of major CVD risk factors.

Lipoprotein(a) [Lp(a)] is a crucial lipid linked to cardiovascular disease (CVD) events, and it is elevated in AA/B individuals compared to W individuals. Moreover, H/L populations exhibit higher rates of obesity, smoking, hypertension, and hypercholesterolemia, all well-known risk factors for cardiovascular issues. Addressing these risk factors and finding effective treatments for CVD in these high-risk populations are critical for enhancing their overall cardiovascular well-being.

A recent analysis of the efficacy and safety of Alirocumab, a (PCSK9) inhibitor for high cholesterol, in three phase 3 trials (ODYSSEY) considered race and ethnicity. Regardless of race and ethnicity, alirocumab significantly reduced LDL-C and Lp(a) levels, effectively addressing lipid-related CVD risk factors in diverse populations. Alirocumab’s advantage is its complementing effect with statins and ezetimibe, making it valuable for patients with varying lipid profiles. It also demonstrated comparable safety across most racial and ethnic groups. As for populations with lower statin use (AA/B and H/L individuals), alirocumab offers a promising option in cardiovascular care. Additionally, it can benefit patients struggling to achieve LDL-C goals despite maximal statin therapy.

Although this analysis provides valuable insights, further research with larger sample sizes and more extended study periods is needed to fully evaluate the efficacy and safety of alirocumab in diverse populations.

Here is where Rubix Life Sciences comes into play. Rubix LS, a pioneering culturally competent research and development company, is committed to addressing these health disparities by bridging the gap in cardiovascular care among different racial and ethnic groups. Rubix LS aims to provide personalized and driven acute diverse, and productive treatment options for individuals at higher risk of ASCVD, including AA/B and H/L patients.

Through extensive research and clinical trials, Rubix LS aims to demonstrate the efficacy and safety of medications like alirocumab in diverse populations. Through Rubix LS’ data, there’s been an increase of 48% in diagnoses to Hispanic origin and African American patient demographics. By analyzing real-world data and exploring potential interactions, Rubix LS seeks to tailor treatment regimens that consider genetic traits and other factors contributing to disparities in health outcomes.

In conclusion, addressing cardiovascular health disparities in diverse populations is crucial. The analysis of alirocumab’s efficacy and safety shows promise for targeted interventions. Companies like Rubix LS offer hope for personalized therapies to reduce the ASCVD burden in high-risk individuals, regardless of race or ethnicity. Together, we can strive for equitable cardiovascular care and healthier futures.

To know more about the efficacy and safety of Alirocumab, click on this link for the details:

Visit to learn more about how the impact of diversity in clinical trials can augment tailored clinical research in the communities that need it the most.



bottom of page